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Abstract
Background:  Autofluorescence imaging is used widely for diagnostic evaluation of various
epithelial malignancies. Cancerous lesions display loss of autofluorescence due to malignant changes
in epithelium and subepithelial stroma. Carcinoma of unknown primary site presents with lymph
node or distant metastasis, for which the site of primary tumour is not detectable. We describe
here the use of autofluorescence imaging for detecting a clinically innocuous appearing occult
malignancy of the palate which upon pathological examination was consistent with a metastatic
squamous cell carcinoma.
Case Description: A submucosal nodule was noted on the right posterior hard palate of a 59-
year-old white female during clinical examination. Examination of this lesion using a multispectral
oral cancer screening device revealed loss of autofluorescence at 405 nm illumination. An excisional
biopsy of this nodule, confirmed the presence of a metastatic squamous cell carcinoma. Four years
ago, this patient was diagnosed with metastatic squamous cell carcinoma of the right mid-jugular
lymph node of unknown primary. She was treated with external beam irradiation and remained
disease free until current presentation.
Conclusion: This case illustrates the important role played by autofluorescence tissue imaging in
diagnosing a metastatic palatal tumour that appeared clinically innocuous and otherwise would not
have been biopsied.
Background
Light-induced tissue autofluorescence examination is cur-
rently considered as a standard of care for screening and
diagnostic evaluation of early neoplastic changes of the
skin, cervix, lung, bladder, gastrointestinal tract and oral
cavity [1-11]. Dysplastic and cancerous tissues often
exhibit decreased blue-green autofluorescence and appear
darker compared to uninvolved mucosa. Most of this
reduction in perceived fluorescence is attributed to dimin-
ished signal (detectable from the surface) that emanates
from collagen crosslink within the subepithelial stroma
[12].
Recently the U.S. Food and Drug Administration has
approved autofluorescence-based oral mucosal screening
devises which are marketed as VELscope and Identafi™
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3000 for early detection of potentially malignant oral
lesions. Here we report of a case to highlight the value of
tissue autofluorescence visualization in diagnosing a
squamous cell carcinoma, metastatic to the palate, which
clinically presented as an innocuous appearing submu-
cosal nodule.
Case Report
A 59-year-old white female was receiving regular dental
treatment at the Special Patient Clinic of the University of
Texas Dental Branch at Houston. During her recent clinic
visit, we noticed a submucosal nodule on her posterior
hard palate during routine oral examination. The patient
was unaware of this lesion. This lesion was covered by
intact mucosa, was non-fluctuant and had the consistency
of an irritation fibroma. This submucosal nodule meas-
ured 0.8 cm in greatest diameter and palpation of this
nodule elicited no tenderness or blanching.
Her medical history is significant for cervical lymph node
metastasis of squamous cell carcinoma from unknown
primary, hypertension, chronic obstructive pulmonary
disease, hypothyroidism and depression. The patient was
diagnosed with squamous cell carcinoma of unknown
primary, metastatic to the right mid jugular lymph nodes
approximately four years ago. Various imaging studies
were performed at the time which failed to identify the
primary site of this tumour. The patient was treated with
a course of external beam radiation therapy to the pharyn-
geal axis and the neck. Her oral mucosa and teeth were
shielded from the direct radiation therapy beams. Patient
had no clinical evidence of either primary or metastatic
tumour during the last four years. Her current medica-
tions include levothyroxine, enalapril malate and fluoxet-
ine. The patient had a 10-pack-year history of smoking
and social consumption of alcohol. The patient's family
history was unremarkable.
Our clinical differential diagnosis for this palatal nodule
included traumatic fibroma and epidermoid cyst. How-
ever, because of her past medical history of metastatic dis-
ease, we examined this nodule using a multispectral oral
cancer screening device (Identafi™ 3000). This submu-
cosal nodule revealed decreased autofluorescence at 405
nm illumination (Figure 1A-C). On the other hand, a clin-
ically similar appearing benign fibroma (arrow) from a
different patient, exhibited normal tissue autofluores-
cence (Figure 1D-F). An excisional biopsy of this submu-
cosal nodule was performed which was diagnosed as
consistent with metastatic squamous cell carcinoma
because of the overlying benign surface epithelium.
Patient was referred to her oncologist for further evalua-
tion and treatment. The clinical protocol for the detection
potentially malignant oral mucosal lesions with Identafi
3000 was reviewed and approved by the Institutional
Review Board of the University of Texas Health Science
Center at Houston. Written informed consents were
obtained from all participants of this clinical study.
Discussion
Increasing need for additional non-invasive tests to aug-
ment conventional white light oral examination has
driven the development of various real-time light-induced
fluorescence visualization devices for detection and delin-
eation of potentially malignant oral lesions [9,13]. The
U.S. Food and Drug administration has approved two oral
cancer screening devices namely, VELscope® (LED Dental,
Inc, White Rock, British Columbia, Canada) and Identafi
3000™ (Trimira™, Houston, Texas) for light-induced fluo-
rescence visualization of oral mucosa. VELscope uses a
blue/violet light (400-460 nm) to illuminate oral mucosa
and a specific filter allows the clinician to visualize tissue
autofluorescence. Identafi 3000 uses multiple illumina-
tion settings namely white, amber (560 nm) and violet
(405 nm) to visualize the oral mucosal reflectance (white
and amber) and fluorescence (violet).
Light-induced tissue fluorescence visualization technolo-
gies are being used increasingly as non-invasive diagnostic
aids to characterize biochemical and structural changes
associated with neoplastic transformation [7,11,14].
These diagnostic tests vary depending on the type of fluor-
ophores being visualized: 1) endogenous fluorophores
(autofluorescence); 2) fluorophores synthesized in tissue
after administration of a precursor drug; 3) fluorophores
injected as exogenous drug. Autofluorescence visual imag-
ing is the most widely used and safest method that has
great promise to enhance the visualization and diagnostic
predictability of potentially malignant lesions. When nor-
mal mucosa is illuminated by high-intensity violet (405
nm with the Identafi™ 3000 system) or blue light (436 nm
with VELscope system), specific components of this
mucosa (fluorophores) emit low-energy light, which is
visualized as the autofluorescence image of the mucosa.
The major fluorophores of oral mucosa include flavin
adenine dinucleotide (FAD) and nicotinamide adenine
dinucleotide (NADH) of the epithelium and cross-linked
collagen and elastin fibers of the underlying lamina pro-
pria. Subepithelial stromal collagen fibers are the predom-
inant source of autofluorescence in oral mucosa [15].
Usually malignant transformation is associated with
thickening of the epithelium, enhanced cellular density
due to increased nuclear cytoplasmic ratio which may
attenuate the excitation leading to a decrease in collagen
autofluorescence. Although the role of autofluorescence
based screening devices such as the Identafi™ 3000 or the
VELscope in oral precancer and cancer diagnosis remains
to be determined, recent studies have documented prom-
ising applications for these devices. Recently, Roblyer et
al. examined light-induced tissue autofluorescence atHead & Neck Oncology 2009, 1:37 http://www.headandneckoncology.org/content/1/1/37
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multiple excitation wave lengths at 365, 380, 405 and 450
nm and demonstrated that they could differentiate the
dysplastic epithelia and carcinoma from histologically
normal mucosa with 95.9% sensitivity and 96.2% specif-
icity [16]. Moreover, subclinical premalignant and malig-
nant lesions that are not visible on routine white light oral
examination become noticeable with direct autofluores-
cence visualization [17]. Recent studies reported that
autofluorescence tissue imaging is more sensitive than
routine white light examination to determine surgical
margins at the primary site that are free of histologic and
molecular features of malignancy or dysplasia [18,19].
Our patient was diagnosed with carcinoma of unknown
primary site (CUP), defined as metastatic carcinoma
present in the lymph nodes with no identifiable primary
tumour despite thorough clinical and radiographic evalu-
ations [20]. The incidence of CUP, which represents up to
7% of all head and neck carcinomas, has reduced in recent
years due to the use of multimodal imaging studies to
identify occult primary tumours [21-24]. Approximately
75% of CUP occurring in the cervical lymph nodes in
which the primary tumours were subsequently identified
originated from the head and neck area, most frequently
from the peritonsillar area and base of the tongue [25].
However, in a significant proportion of CUP patients, the
primary tumour site may remain undetected for several
years as in the current case [24,26]. The patient in our case
had no clinical evidence of primary tumour or recurrence
for 4 years until she presented with the described palatal
tumour. We believe that this tumour represents a second
metastasis and not a primary tumour because the surface
epithelium overlying this submucosal tumour was not
directly connected to the tumour island and did not
exhibit histologic features of dysplasia or malignancy as
noted with primary oral squamous cell carcinomas. To
our knowledge, this is the first case to report the use of tis-
sue autofluorescence imaging to diagnose an occult meta-
static squamous cell carcinoma to the palatal mucosa. In
the current case, it appears that metastatic tumour islands
An innocuous appearing submucosal nodule (arrow) was noted on the posterior hard palate of a 59-year-old white female dur- ing standard clinical examination which upon examination with a multispectral oral cancer screening device (Identafi™ 3000),  revealed loss of autofluorescence Figure 1
An innocuous appearing submucosal nodule (arrow) was noted on the posterior hard palate of a 59-year-old 
white female during standard clinical examination which upon examination with a multispectral oral cancer 
screening device (Identafi™ 3000), revealed loss of autofluorescence. A: White light image of the metastatic lesion; B: 
Fluorescence image at 405 nm illumination; C: Microscopic examination of the biopsy revealed the presence of metastatic 
squamous carcinoma, Bar = 100 μM (C). In comparison, a similar appearing benign fibroma (arrow) exhibits normal autofluo-
rescence. D: White light image of a benign fibroma; E: Fluorescence image at 405 nm illumination; F: Microscopic examination 
of the biopsy revealed reactive fibrous hyperplasia, Bar = 100 μM.Publish with BioMed Central    and   every 
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within the subepithelial stroma disrupted stromal colla-
gen fibers leading to the loss of stromal autofluorescence.
In contrast, a clinically similar appearing benign fibroma
comprised of dense subepithelial fibrous tissue revealed
normal autofluorescence. Certainly, multispectral tissue
autofluorescence is a new and powerful technology that
can be used for multiple diagnostic applications.
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